Maintenance therapy and drug holiday in sarcoma patients: systematic review

References

• Moher D, Liberati A, Tetzlaff J, et al. preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Müller CR, Smeland S, Bauer HC, et al. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol. 2005;44(5):475–480.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. JCO. 2015;33(20):2279–2287.
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Jia SF, Griffin J, et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. JCO. 1992;10(8):1310–1316.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. JCO. 2008;26(4):633–638.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. JCO. 2005;23(9):2004–2011.
   PubMed Web of Science ®Google Scholar
• Penel N, Adenis A, Bocci G. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going. Crit Rev Oncol Hematol. 2012;82(1):40–50.
   PubMed Web of Science ®Google Scholar
• Hill SA, Lonergan SJ, Denekamp J, et al. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer. 1993;29(9):1320–1324.
   Web of Science ®Google Scholar
• Casanova M, Ferrari A, Bisogno G, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer. 2004;101(7):1664–1671.
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Ichante J-L, Nguyen L, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma—a report from the Societe Francaise des Cancers et Leucemies de l’Enfant et de l’Adolescent (SFCE). Eur J Cancer. 2012;48(15):2409–2416.
   PubMed Web of Science ®Google Scholar
• Bisogno G, De Salvo GL, Bergeron C, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(11):1566–1575.
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Boos J, Beske F, et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer. 2008;50(4):739–745.
   PubMed Web of Science ®Google Scholar
• D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. JCO. 2005;23(28):7135–7142.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial. JCO. 2015;33(25):2797–2802.
   PubMed Web of Science ®Google Scholar
• Chisholm JC, Merks JHM, Casanova M, et al. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer. 2017;83:177–184.
   PubMed Web of Science ®Google Scholar
• Chawla SP, Staddon AP, Baker LH, al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. JCO. 2012;30(1):78–84.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. JCO. 2013;31(19):2485–2492.
   PubMed Web of Science ®Google Scholar
• Pacey S, Ratain MJ, Flaherty KT, et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs. 2011;29(3):481–488.
   PubMed Web of Science ®Google Scholar
• Penel N, Decoupigny E, Tresch-Bruneel E, et al. Exceptional long-lasting clinical benefit of trabectedin in a patient with metastatic undifferentiated pleomorphic sarcoma: postscriptum from the T-Dis trial. Am J Clin Oncol. 2019;42(9):737.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Domont J, et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol. 2015;16(3):312–319.
   PubMed Web of Science ®Google Scholar
• Kotecki N, Le Cesne A, Tresch-Bruneel E, et al. Impact of trabectedin interruption and subsequent rechallenge on progression in patients with advanced soft tissue sarcoma: Long-term follow-up of the T-DIS trial. Am J Clin Oncol. 2018;41(11):1094–1100.
   PubMed Web of Science ®Google Scholar
• Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. JCO. 2007;25(9):1107–1113.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11(10):942–949.
   PubMed Web of Science ®Google Scholar
• Agulnik M, Yarber JL, Okuno SH, et al. Open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24(1):257–263.
   PubMed Web of Science ®Google Scholar
• Tap WD, Wagner AJ, Papai Z, et al. ANNOUNCE: a randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). JCO. 2019;37(18_suppl):LBA3–LBA3.
   Web of Science ®Google Scholar
• Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488–497.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Kindler H, Gelderblom H, et al. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Ann Oncol. 2017;28(3):541–546.
   PubMed Web of Science ®Google Scholar